SG10202112588PA - Amine prodrugs of pharmaceutical compounds - Google Patents

Amine prodrugs of pharmaceutical compounds

Info

Publication number
SG10202112588PA
SG10202112588PA SG10202112588PA SG10202112588PA SG10202112588PA SG 10202112588P A SG10202112588P A SG 10202112588PA SG 10202112588P A SG10202112588P A SG 10202112588PA SG 10202112588P A SG10202112588P A SG 10202112588PA SG 10202112588P A SG10202112588P A SG 10202112588PA
Authority
SG
Singapore
Prior art keywords
alkyl
prodrug
riluzole
substituted
unsubstituted
Prior art date
Application number
SG10202112588PA
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of SG10202112588PA publication Critical patent/SG10202112588PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • C07F9/6541Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG10202112588PA 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds SG10202112588PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562257533P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
SG10202112588PA true SG10202112588PA (en) 2021-12-30

Family

ID=58717793

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202112588PA SG10202112588PA (en) 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds
SG11201803645PA SG11201803645PA (en) 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201803645PA SG11201803645PA (en) 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds

Country Status (8)

Country Link
US (2) US20180318268A1 (enExample)
EP (1) EP3377111B1 (enExample)
JP (1) JP7110094B2 (enExample)
KR (1) KR20180084049A (enExample)
ES (1) ES2969792T3 (enExample)
IL (1) IL259394B (enExample)
SG (2) SG10202112588PA (enExample)
WO (1) WO2017087594A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6700293B2 (ja) 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドBiohaven Pharmaceutical Holding Company Ltd. リルゾールプロドラッグおよびそれらの使用
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
WO2023115002A1 (en) * 2021-12-16 2023-06-22 Terran Biosciences Inc. Analogs of 4-bromo-2,5-dimethoxyphenethylamine
US20250129064A1 (en) * 2022-01-24 2025-04-24 Terran Biosciences Inc. Prodrugs of 2-bromo-lsd (2-bromolysergic acid diethylamide)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス,インコーポレーテッド ノルケタミンおよびケタミン/ノルケタミンプロドラッグの鎮痛的使用
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
AR051475A1 (es) 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規2’−c−メチル及び4’−c−メチルヌクレオシド誘導体
EP2203435B1 (en) 2007-09-17 2018-07-18 Enanta Pharmaceuticals, Inc. 6, 11-bridged biaryl macrolides
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US20130030359A1 (en) * 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011109767A2 (en) * 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
PT2858987T (pt) 2012-06-11 2018-07-04 Bristol Myers Squibb Co Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida
WO2014011695A2 (en) * 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors

Also Published As

Publication number Publication date
IL259394A (en) 2018-07-31
SG11201803645PA (en) 2018-06-28
US11083711B2 (en) 2021-08-10
IL259394B (en) 2022-04-01
US20190365721A1 (en) 2019-12-05
JP2019501877A (ja) 2019-01-24
EP3377111A1 (en) 2018-09-26
WO2017087594A1 (en) 2017-05-26
EP3377111B1 (en) 2023-11-29
KR20180084049A (ko) 2018-07-24
ES2969792T3 (es) 2024-05-22
US20180318268A1 (en) 2018-11-08
EP3377111A4 (en) 2019-11-13
JP7110094B2 (ja) 2022-08-01

Similar Documents

Publication Publication Date Title
SG10202112588PA (en) Amine prodrugs of pharmaceutical compounds
ES2612033T3 (es) Procedimiento para la preparación de bosentán
EA025471B1 (ru) Способы получения тубулизинов
WO2014152763A1 (en) Cephalosporin compositions and methods of manufacture
EA028395B1 (ru) Способы получения фенилацетата l-орнитина
KR20080109088A (ko) 로수바스타틴 아연 염
AU2019298749B2 (en) Intermediates in the synthesis of C3-substituted cephalosporins
US8318936B2 (en) Method for producing N-methylnaltrexone bromide
AU2007208965B2 (en) A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof
US8952022B2 (en) Pure erlotinib
US20170036991A1 (en) Isolation and purification of 6-aminocaproic acid
CZ300093B6 (cs) Zpusob prípravy thiamethoxamu
CA2682822A1 (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
RU2006142768A (ru) Способ получения бисульфата атазанавира
ES2984183T3 (es) Proceso para preparar derivados de anfetamina acilados
CA2671816A1 (en) Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
ES2289650T3 (es) Sal monosodica del acido 3-piridil-1-hidroxietiliden-1,1-bifosfonico amorfa y procedimiento para la preparacion de la misma.
WO2019021290A1 (en) PROCESS FOR THE PREPARATION OF GLYCOPYRROLATE TOSYLATE
DE69707639T2 (de) Verfahren zur herstellung einer aktivierten aminosäure
US20100210675A1 (en) Solvent-free crystalline form of naltrexone
AU612414B2 (en) Cephalosporin derivatives with improved pharmacokinetics, process for their preparation, pharmaceutical compositions in which they are present and synthesis intermediate
KR102500243B1 (ko) 5-(c1~c4 알킬) 테트라졸의 합성방법
US10100005B1 (en) Mesalazine derivatives
TW201329033A (zh) 3-烴基-3-甲基丁酸或其鈣鹽之製備方法
ES2386173B1 (es) Proceso de preparación de un antagonista del receptor de la endotelina